Related Experiment Video

Updated: Sep 28, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer

Elżbieta Fiedor1, Karolina Zajda1, Ewa L Gregoraszczuk2

  • 1Department of Physiology and Toxicology of Reproduction, Institute of Zoology and Biomedical Research, Jagiellonian University in Kraków, Krakow, Poland.

Cancer Genomics & Proteomics
|July 7, 2018
PubMed
Abstract

Insights

Leptin receptor antagonists SHLA and Lan2 can reduce histone deacetylase (HDAC) levels in ovarian cancer cells. These antagonists counteract leptin

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Histone deacetylases (HDACs) are frequently overexpressed in cancer cells.
  • Leptin can influence HDAC levels, suggesting a role in carcinogenesis.
  • Leptin receptor antagonists may offer a novel therapeutic strategy.

Purpose of the Study:

  • To investigate the effect of leptin receptor antagonists (SHLA and Lan2) on HDAC expression in ovarian cancer cells.
  • To determine if these antagonists can counteract leptin-induced changes in HDAC levels.
  • To explore cell-type-specific responses to leptin and its receptor antagonists.

Main Methods:

  • Evaluation of HDAC expression in ovarian epithelial (OVCAR-3, CaOV3) and folliculoma (COV434, KGN) cells.
  • Treatment of cells with leptin and leptin receptor antagonists (SHLA, Lan2).
  • Comparative analysis of antagonist potency and cell-specific effects.

Main Results:

  • Ovarian epithelial cells exhibited higher HDAC expression than folliculoma cells.
  • Leptin increased HDACs in OVCAR-3 cells; SHLA was more potent than Lan2.
  • Antagonist effects on HDACs varied by cell type, with Lan2 showing greater potency in COV434 cells.

Conclusions:

  • SHLA and Lan2 demonstrate cell-type-dependent efficacy in mitigating leptin's effects on HDAC expression.
  • This study is the first to examine leptin receptor blockers as potential HDAC inhibitors in ovarian cancer.
  • Findings suggest a potential therapeutic role for leptin receptor antagonists in ovarian cancer treatment.
Keywords:
HDACs expressionOvarian cancerleptinleptin receptors blocker

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Isolation of Targeted Hypothalamic Neurons for Studies of Hormonal, Metabolic, and Electrical Regulation09:29

Isolation of Targeted Hypothalamic Neurons for Studies of Hormonal, Metabolic, and Electrical Regulation

Published on: August 4, 2023

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...